Description
Used in the treatment of:
- HER2-positive breast cancer (early or metastatic)
- HER2-positive metastatic gastric and gastroesophageal junction adenocarcinoma
Trastuzumab is a monoclonal antibody that binds to the HER2 receptor, inhibiting cancer cell growth and inducing antibody-dependent cellular cytotoxicity.



